Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

NASDAQ:CGEM

Overview | Financials
Company Name Cullinan Oncology, Inc.
Symbol CGEM
Currency USD
Price 11.6
Market Cap 675,440,160
Dividend Yield 0%
52-week-range 9.24 - 30.189
Industry Biotechnology
Sector Healthcare
CEO Mr. Nadim Ahmed
Website https://www.cullinanoncology.com

An error occurred while fetching data.

About Cullinan Oncology, Inc.

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients

Related Stocks

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

14.6 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

6.76 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Financials

Numbers are in millions USD

Numbers are in millions USD